文献速递白血病造血干细胞移植与细胞治疗

B系急性淋巴细胞白血病异基因造血细胞移植后贝林妥欧单抗维持治疗

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2022-01-01

单中心2期研究评估高危B系急性淋巴细胞白血病患者异基因造血细胞移植后1年内每3个月给予4个周期贝林妥欧单抗的可行性,21例可评估患者中57%完成4个周期,中性粒细胞减少为唯一4级不良事件(19%),1年总生存率85%、无进展生存率71%、非复发死亡率0%。

要点

  • 移植后中位78天开始贝林妥欧单抗,21例中12例(57%)完成全部4个周期。
  • 中性粒细胞减少是唯一4级不良事件(19%),细胞因子释放综合征和神经毒性发生率低。
  • 1年总生存率85%、无进展生存率71%、非复发死亡率0%,中位随访14.3个月。

核心结论

  • 异基因造血细胞移植后给予贝林妥欧单抗是可行的,其获益取决于治疗时的免疫微环境。

研究设计与样本

  • 单中心2期研究,评估高危B系急性淋巴细胞白血病患者异基因造血细胞移植后1年内每3个月给予4个周期贝林妥欧单抗的可行性。
  • 共入组23例患者,其中21例接受至少1个周期贝林妥欧单抗并纳入分析。

主要发现

  • 移植至首个贝林妥欧单抗周期的中位时间为78天(范围44至105天)。
  • 12例患者(57%)完成全部4个治疗周期。
  • 中性粒细胞减少是唯一的4级不良事件(19%)。
  • 细胞因子释放综合征发生率为5%(G1),神经毒性发生率为5%(G2)。
  • 急性移植物抗宿主病2至4级和3至4级的累积发生率分别为33%和5%;慢性移植物抗宿主病轻度2例(10%)、中度1例(5%)。

关键数值与推荐

  • 中位随访14.3个月时,1年总生存率为85%,无进展生存率为71%,非复发死亡率为0%。
  • 与57例同期患者匹配分析,两组间贝林妥欧单抗疗效无显著差异。
  • 应答者具有较高比例的记忆性CD8 T细胞亚群;无应答者T细胞缺陷且表达更多抑制性检查点分子,包括T细胞免疫球蛋白和黏蛋白结构域3(TIM3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 study evaluating the feasibility of 4 cycles of blinatumomab administered every 3 months during the first year after HCT in an effort to mitigate relapse in high-risk ALL patients. Twenty-one of 23 enrolled patients received at least 1 cycle of blinatumomab and were included in the analysis. The median time from HCT to the first cycle of blinatumomab was 78 days (range, 44 to 105). Twelve patients (57%) completed all 4 treatment cycles. Neutropenia was the only grade 4 adverse event (19%). Rates of cytokine release (5% G1) and neurotoxicity (5% G2) were minimal. The cumulative incidence of acute graft-versus-host disease (GVHD) grades 2 to 4 and 3 to 4 were 33% and 5%, respectively; 2 cases of mild (10%) and 1 case of moderate (5%) chronic GVHD were noted. With a median follow-up of 14.3 months, the 1-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) rates were 85%, 71%, and 0%, respectively. In a matched analysis with a contemporary cohort of 57 patients, we found no significant difference between groups regarding blinatumomab's efficacy. Correlative studies of baseline and posttreatment samples identified patients with specific T-cell profiles as "responders" or "nonresponders" to therapy. Responders had higher proportions of effector memory CD8 T-cell subsets. Nonresponders were T-cell deficient and expressed more inhibitory checkpoint molecules, including T-cell immunoglobulin and mucin domain 3 (TIM3). We found that blinatumomab postallogeneic HCT is feasible, and its benefit is dependent on the immune milieu at time of treatment. This paper is posted on ClinicalTrials.gov, study ID: NCT02807883.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gaballa MR, Banerjee P, Milton DR, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022. PMID: 34914826. doi:10.1182/blood.2021013290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。